Actively Recruiting

Phase Not Applicable
Age: 18Years - 80Years
All Genders
Healthy Volunteers
NCT05119842

APrevent-VOIS-Implant-002 - a Two-Part, Open-Label, Non-Randomized Multicenter Study

Led by APrevent Biotech GmbH · Updated on 2025-02-06

30

Participants Needed

7

Research Sites

354 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a prospective, 2-part, multi-center, open-label, non-randomized clinical trial to assess safety and effectiveness of APrevent® VOIS Implants for the treatment of patients with Unilateral Vocal Fold Paralysis (UVFP). In total 30 evaluable patients are planned to be enrolled.

CONDITIONS

Official Title

APrevent-VOIS-Implant-002 - a Two-Part, Open-Label, Non-Randomized Multicenter Study

Who Can Participate

Age: 18Years - 80Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Male and female patients between 18 and 80 years
  • Diagnosed with permanent unilateral vocal fold paralysis (UVFP) and insufficient glottal closure
  • Significant voice disorder with Grade 2 or higher on the GRBAS Scale and Voice Handicap Index (VHI-30) score above 33
  • Ability to understand the study purpose, risks, and requirements
  • Willingness and ability to cooperate and comply with all study procedures
  • Availability to participate for the entire study duration and provide informed consent
Not Eligible

You will not qualify if you...

  • Any other significant disease or disorder that may increase risk or affect study results
  • Scheduled elective surgery or procedures requiring general anesthesia during the study
  • Bilateral vocal fold paralysis
  • Recent injection medialization laryngoplasty within the approved resorption period
  • Presence of structural vocal fold lesions such as polyps or nodules
  • Presence of oropharyngeal or laryngeal tumors
  • Diagnosed severe obstructive sleep apnea (OSA)
  • History of total cordectomy
  • Previous laryngeal framework surgery (any thyroplasty or arytenoid adduction)
  • History of tracheostomy
  • Acute systemic infection at screening or shortly before surgery
  • Significant non-laryngeal speech abnormality (severe dysarthria)
  • Severe coagulopathy
  • Females pregnant, lactating, or planning pregnancy
  • Bilateral Grade III-IV hypertrophic tonsils
  • Poorly controlled diabetes mellitus with poor wound healing history

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 7 locations

1

Mayo Clinic - Phoenix

Phoenix, Arizona, United States, 85054

Actively Recruiting

2

Greater Baltimore Medical Center

Baltimore, Maryland, United States, 21204

Actively Recruiting

3

Cleveland Clinic

Cleveland, Ohio, United States, 44106

Not Yet Recruiting

4

The University of Texas Health Science Center at Houston

Houston, Texas, United States, 77030

Actively Recruiting

5

Medical University of Vienna

Vienna, Austria

Actively Recruiting

6

SRH Wald-Klinikum Gera

Gera, Germany

Actively Recruiting

7

University Medical Center

Hamburg, Germany

Actively Recruiting

Loading map...

Research Team

B

Berit Schneider-Stickler, Prof

CONTACT

M

Matthias Leonhard, Dr

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

APrevent-VOIS-Implant-002 - a Two-Part, Open-Label, Non-Randomized Multicenter Study | DecenTrialz